PT857068E - Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio - Google Patents

Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio

Info

Publication number
PT857068E
PT857068E PT96930819T PT96930819T PT857068E PT 857068 E PT857068 E PT 857068E PT 96930819 T PT96930819 T PT 96930819T PT 96930819 T PT96930819 T PT 96930819T PT 857068 E PT857068 E PT 857068E
Authority
PT
Portugal
Prior art keywords
sensitized
cells
antigenic
infectious diseases
immunotherapy
Prior art date
Application number
PT96930819T
Other languages
English (en)
Portuguese (pt)
Inventor
Pramod K Srivastava
Original Assignee
Univ Fordham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Fordham filed Critical Univ Fordham
Publication of PT857068E publication Critical patent/PT857068E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PT96930819T 1995-09-13 1996-09-11 Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio PT857068E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/527,546 US5985270A (en) 1995-09-13 1995-09-13 Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes

Publications (1)

Publication Number Publication Date
PT857068E true PT857068E (pt) 2004-09-30

Family

ID=24101899

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96930819T PT857068E (pt) 1995-09-13 1996-09-11 Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio

Country Status (12)

Country Link
US (2) US5985270A (2)
EP (1) EP0857068B1 (2)
JP (1) JPH11512433A (2)
AT (1) ATE264910T1 (2)
AU (1) AU728929B2 (2)
CA (1) CA2232002A1 (2)
DE (1) DE69632261T2 (2)
DK (1) DK0857068T3 (2)
ES (1) ES2219696T3 (2)
PT (1) PT857068E (2)
WO (1) WO1997010002A1 (2)
ZA (1) ZA967756B (2)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US6719974B1 (en) 1995-08-18 2004-04-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1997006821A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6761892B1 (en) 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6773707B1 (en) 1995-08-18 2004-08-10 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US6331299B1 (en) 1995-08-18 2001-12-18 Sloan-Kettering Institute For Cancer Research Method for treatment of cancer and infectious disease and compositions useful in same
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
IN183280B (2) 1996-09-20 1999-10-30 Univ New Mexico
US7157089B1 (en) 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
KR20060111731A (ko) * 1997-08-05 2006-10-27 스트레스젠 바이오테크놀러지스 코포레이션 사람 유두종 바이러스 항원과 스트레스 단백질을 포함하는융합 단백질을 포함하는 조성물에 의해 유도된 사람 유두종바이러스 항원에 대한 면역 반응
EP1027070A4 (en) * 1997-10-31 2004-08-18 Sloan Kettering Institutefor C CONJUGATES FROM HEAT SHOCK PROTEIN-BINDING PEPTIDES
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
JP4768122B2 (ja) * 1998-02-20 2011-09-07 ユニバーシティー オブ マイアミ 改変型熱ショックタンパク質−抗原性ペプチド複合体
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
EP1064390A4 (en) * 1998-03-20 2002-06-12 Genzyme Corp Enhanced anti-tumor immunity
AU773561B2 (en) 1998-03-30 2004-05-27 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
US6949339B1 (en) * 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
US6858386B1 (en) 1998-05-21 2005-02-22 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20020142974A1 (en) * 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
WO2000028031A2 (en) * 1998-11-10 2000-05-18 Emory University Mitogenic regulators
US6730302B1 (en) * 1998-11-24 2004-05-04 Bristol-Myers Squibb Company Intracellular targeted delivery of compounds by 70 kD heat shock protein
CA2378097A1 (en) 1999-07-08 2001-01-18 Stressgen Biotechnologies Corporation Induction of a th1-like response in vitro
GB9919733D0 (en) * 1999-08-19 1999-10-20 Colaco Camilo Vaccines against intracellular pathogens
AUPQ233799A0 (en) 1999-08-19 1999-09-09 Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales Recombinant sub-unit vaccine
US7378096B2 (en) 1999-09-30 2008-05-27 Health Research, Inc. Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
WO2001023421A2 (en) * 1999-09-30 2001-04-05 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
JP3524537B2 (ja) * 1999-11-22 2004-05-10 ディアデクサス インコーポレーテッド 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法
US7238471B1 (en) * 1999-11-23 2007-07-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating breast cancer
US20020048777A1 (en) * 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
IL150113A0 (en) * 1999-12-15 2002-12-01 Peptor Ltd Fragments and antagonists of heat shock protein 60
CA2394504A1 (en) * 1999-12-15 2001-06-21 Peptor Ltd. Fragments and antagonists of heat shock protein 60
GB0004547D0 (en) * 2000-02-23 2000-04-19 Immunobiology Ltd Screening method for novel vaccine candidates and compositions obtained thereby
JP2004510408A (ja) * 2000-05-26 2004-04-08 ディアデクサス　インコーポレーテッド 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法
US7179462B2 (en) 2000-06-02 2007-02-20 University Of Connecticut Health Center α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7186515B1 (en) 2000-06-02 2007-03-06 University Of Connecticut Health Center Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
DK1296711T3 (da) * 2000-06-26 2006-08-28 Stressgen Biotechnologies Corp HPV-E7 til behandling af humant papillomavirus
CA2422867A1 (en) * 2000-09-15 2002-04-25 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
US20020172682A1 (en) * 2000-10-20 2002-11-21 University Of Connecticut Health Center Using heat shock proteins to increase immune response
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
WO2002057795A2 (en) 2001-01-19 2002-07-25 Cambridge Scientific, Inc. Methods of diagnosis and treatment of osteoporosis
US6921534B2 (en) 2001-02-05 2005-07-26 Stressgen Biotechnologies Corporation Hepatitis B virus treatment
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
EP2848255B1 (en) 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
WO2002077012A2 (en) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
HK1079705A1 (zh) * 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
EP1551957A4 (en) 2001-10-01 2007-01-24 Univ Duke ISOLATED POLYPEPTIDE OF THE GRP94 LIGANDEN BINDING DOMAIN AND NUCLEIC ACID, CRYSTALLINE FORM THEREOF, CODING THEREOF, AND SCRAPPING METHOD WHERE IT IS USED
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
ES2526822T3 (es) 2002-01-31 2015-01-15 Andromeda Bio Tech Ltd. Péptidos hsp y análogos para la modulación de respuestas inmunes mediante células presentadoras de antígeno
US7118753B2 (en) * 2002-02-08 2006-10-10 Anawrahta Biotech Co., Ltd. Enhancing cell-based immunotherapy
CA2477417A1 (en) * 2002-02-28 2003-09-04 Antigenics Inc. Methods and products based on oligomerization of stress proteins
US6984389B2 (en) 2002-04-25 2006-01-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003090686A2 (en) 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
WO2003092624A2 (en) * 2002-05-02 2003-11-13 University Of Connecticut Health Center Use of heat shock proteins to enhance efficacy of antibody therapeutics
EP1509244B1 (en) * 2002-06-06 2011-07-27 Immunicum AB New method and composition for producing a cellular allogeneic vaccine
CA2501577A1 (en) * 2002-10-07 2004-04-22 Antigenics, Inc. Heat shock protein binding fragments of cd91, and uses thereof
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
RU2324493C2 (ru) * 2003-02-20 2008-05-20 Юниверсити Оф Коннектикут Хелт Сентер Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
WO2004074454A2 (en) 2003-02-20 2004-09-02 University Of Connecticut Health Center Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
CA2517396A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
JP2007505147A (ja) 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
KR20110017356A (ko) 2008-03-20 2011-02-21 유니버시티 오브 마이애미 열충격 단백질 ｇｐ96 백신접종 및 이를 사용하는 방법
AU2009262670B2 (en) 2008-06-26 2013-06-20 Zevra Denmark A/S Use of Hsp70 as a regulator of enzymatic activity
WO2010002983A2 (en) * 2008-07-03 2010-01-07 Duke University Composition and methods for eliciting an immune response
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
EP2374813A1 (en) 2008-12-03 2011-10-12 Proyecto de Biomedicina Cima, S.L. Use of phenol-soluble modulins for vaccine development
AU2010232490B2 (en) 2009-04-03 2016-08-11 Agenus Inc. Methods for preparing and using multichaperone-antigen complexes
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
JP2010235611A (ja) * 2010-05-10 2010-10-21 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
CA2817773A1 (en) 2010-11-30 2012-06-07 Orphazyme Aps Methods for increasing intracellular activity of hsp70
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
AU2015317447B2 (en) 2014-09-15 2021-02-25 Zevra Denmark A/S Arimoclomol formulation
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
SG10201912485PA (en) 2015-05-13 2020-02-27 Agenus Inc Vaccines for treatment and prevention of cancer
CN105176957A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 肾癌相关肽和热休克蛋白形成的复合物及其应用
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
DK3782624T3 (da) 2016-04-29 2025-12-15 Zevra Denmark As Arimoclomol til behandling af glucocerebrosidase-associerede lidelser
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
WO1994029459A1 (en) * 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1989012455A1 (en) * 1988-06-15 1989-12-28 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
WO1990002564A1 (en) * 1988-09-12 1990-03-22 Codon Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi
US5232833A (en) * 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5188964A (en) * 1990-04-12 1993-02-23 Board Of Regents, The University Of Texas System Method and kit for the prognostication of breast cancer patient via heat shock/stress protein determination
GB9016315D0 (en) * 1990-07-25 1990-09-12 Burnie James P Medicaments
GB9024320D0 (en) * 1990-11-08 1990-12-19 Univ London Treatment of uveitis
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
GB9200949D0 (en) * 1992-01-17 1992-03-11 Medical Res Council Diagnostic peptides
DE69333110T2 (de) * 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
FR2688227A1 (fr) * 1992-03-04 1993-09-10 Inst Nat Sante Rech Med Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques.
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2130089A1 (en) * 1992-03-09 1993-09-16 Aldo Mancini Protein compound, coding nucleotide sequences, producing cell line and uses thereof
EP0636248A4 (en) * 1992-04-14 1996-11-13 Univ Duke METHOD FOR DETECTING P53 AND HSP70 COMPLEX CONTAINING TUMORS.
WO1994002156A1 (en) * 1992-07-16 1994-02-03 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate t cells
IL102687A (en) * 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
GB9223816D0 (en) * 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5997873A (en) * 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5680984A (en) * 1994-05-13 1997-10-28 Matsushita Electric Industrial Co., Ltd. Apparatus and method for mounting soldering balls onto surfaces of electronic components
DE19502985A1 (de) * 1995-01-31 1996-08-01 Deutsche Telekom Ag Steckverbindung für ein optisches Bauelement
WO1997006821A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
WO1997026910A2 (de) * 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
DE19602985A1 (de) * 1996-01-27 1997-07-31 Max Delbrueck Centrum Tumorzellimpfstoff für die Immuntheraphie von malignen Tumoren
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Also Published As

Publication number Publication date
JPH11512433A (ja) 1999-10-26
ZA967756B (en) 1997-04-16
US5985270A (en) 1999-11-16
ES2219696T3 (es) 2004-12-01
DE69632261T2 (de) 2005-04-14
US6156302A (en) 2000-12-05
DE69632261D1 (de) 2004-05-27
EP0857068A1 (en) 1998-08-12
EP0857068A4 (en) 2000-01-19
EP0857068B1 (en) 2004-04-21
CA2232002A1 (en) 1997-03-20
AU6973596A (en) 1997-04-01
ATE264910T1 (de) 2004-05-15
DK0857068T3 (da) 2004-08-16
AU728929B2 (en) 2001-01-18
WO1997010002A1 (en) 1997-03-20

Similar Documents

Publication Publication Date Title
PT857068E (pt) Imunoterapia do cancro e doencas infecciosas utilizando celulas que apresentam antigenios sensibilizadas com complexos de proteina de choque termico-antigenio
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
ATE127345T1 (de) Stressproteine und verwendungen dafür.
CY1114855T1 (el) Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1
EA199800272A1 (ru) Фактор, стимулирующий дендритные клетки
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
FI912016A0 (fi) In vitro -menetelmä antigeenispesifisten ihmisen monoklonaalisten vasta-aineiden valmistamiseksi
GB2255093A (en) Hiv-1 core protein fragments
DE68926859D1 (de) Natürlicher killerzellen-stimulationsfaktor
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DE69824023D1 (de) Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
DK0412766T3 (da) Peptidfragmenter af HIV
DK0687300T3 (da) LO-CD2a-antistof og anvendelser deraf til inhibering af T-celle-aktivering og -proliferation
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
Le et al. Synthesis of alpha and gamma interferons by a human cutaneous lymphoma with helper T-cell phenotype
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
MXPA04000652A (es) Identificacion de antigenos especificos del tumor por medio de seleccion de bibliotecas de acido desoxirribonucleico complementario con sueros y uso de antigenos en tratamiento de tumores.
AU6435596A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
DE69322960D1 (de) Empfängnisverhütender impfstoff
FI913475A0 (fi) Klass ii protein med immunologiska baerar- och foerstaerkningsegenskaper fraon yttermembranen i neisseria meningitidis och vaccin innehaollande detta.